<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01827605</url>
  </required_header>
  <id_info>
    <org_study_id>FIL_FLAZ-12</org_study_id>
    <nct_id>NCT01827605</nct_id>
  </id_info>
  <brief_title>A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)</brief_title>
  <official_title>A Phase III Multicenter,Randomized Study Comparing Consolidation With 90yttrium-Labeled Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy Vs Autologous Stem Cell Transplantation (ASCT) in Patients With Relapsed/Refractory Follicular Lymphoma (FL) Aged 18-65 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Italiana Linfomi ONLUS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Italiana Linfomi ONLUS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase III, multicenter, open-label, randomized and controlled study to compare the
      efficacy of a consolidation therapy with RIT versus ASCT in patients with FL in CR or PR
      after second or third line chemotherapy supplemented with rituximab.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase III, multicenter, open-label, randomized and controlled study to compare the
      efficacy of a consolidation therapy with RIT vs. ASCT in patients with FL in CR or PR after
      second or third line chemotherapy supplemented with rituximab. Patients with FL will be
      eligible for screening at the time of relapsed or refractory disease after two or less
      chemotherapy lines at least one containing rituximab.

      This study will be conducted in six steps as follows. Screening Phase, Enrolment and
      Induction chemotherapy (STEP I) Randomization (STEP II) Stem cell mobilization and collection
      (STEP III) Consolidation (RIT vs ASCT) (STEP IV) Maintenance (STEP V) Follow-up Phase (STEP
      VI)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival from randomization (rPFS)</measure>
    <time_frame>36 months</time_frame>
    <description>PFS will be defined as the time between the date of randomization and the date of disease progression, relapse or death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival from randomization (rOS)</measure>
    <time_frame>36 months</time_frame>
    <description>OS will be defined as the time between the date of randomization and the date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival (EFS)</measure>
    <time_frame>36 months</time_frame>
    <description>EFS will be measured from the date of randomization to the date of any treatment failure including death, disease progression or relapse, discontinuation of treatment for any reason (toxicity, patient preference, initiation of new treatment without documented progression).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Free Survival from randomization (TFS)</measure>
    <time_frame>36 months</time_frame>
    <description>TFS will be defined as the time between the date of the end of primary treatment until the institution of the next unplanned chemotherapy in randomized population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival from enrolment (ePFS)</measure>
    <time_frame>42 months</time_frame>
    <description>PFS will be defined as the time between the date of enrolment and the date of disease progression, relapse or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival from enrolment (eOS)</measure>
    <time_frame>42 months</time_frame>
    <description>OS will be defined as the time between the date of enrolment and the date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR) Rate</measure>
    <time_frame>At the end of the consolidation phase (6 months)</time_frame>
    <description>Proportion of CR according to the Cheson 2007 response criteria at the end of consolidation phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>At the end of the consolidation phase (6 months)</time_frame>
    <description>ORR at the end of the consolidation phase is defined as Complete Response (CR) or Partial Response according to the Cheson 2007 response criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>42 months</time_frame>
    <description>Incidence of grade 3 or higher Toxicity measured by CTCAE v.4.03 during therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL)</measure>
    <time_frame>42 months</time_frame>
    <description>QoL will be measured during the trial throught the EORTC QLQ-30 and Euro-qol (EQ-5D) questionnaires.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental Cost-Effectiveness Ratio (ICER)</measure>
    <time_frame>36 months</time_frame>
    <description>ICER will be calculated by dividing the difference in mean total costs arms by the difference in the mean effects. The ICER will be calculated for the principal clinical effect measures of the trial. (i.e. PFS and OS) and for QALYs. QALYs will be calculated multiplying the amount of time a patient spent in a particular health state by the utilities estimated using the EQ-5D questionnaires.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular Response rate (MR)</measure>
    <time_frame>36 months</time_frame>
    <description>Rate of MR will be defined as the proportion of patients achieving PCR negativity after the consolidation phase and during follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular Response rate conversion (cMR)</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of conversion will be defined as the proportion of patients with baseline PCR-positivity converting to PCR-negativity during treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular Relapse Rate (MRR)</measure>
    <time_frame>24 months</time_frame>
    <description>Rate of molecular relapse will be defined as the proportion of patients with PCR-negativity after treatment converting to PCR-positivity during the first two years of follow-up.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">265</enrollment>
  <condition>Relapsed Follicular Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm A RIT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion of 90Y Ibritumomab Tiuxetan if the patient has less than 25% BM infiltration at the pre-consolidation restaging (0.4 mCi/kg if platelets ≥150,000/mmc, 0.3 mCi/kg if platelets are between 100.000 and 150,000/mmc). Zevalin® will be delivered as per indications and should thus be provided at expenses following regular supplies procedures.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM B ASCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BEAM conditioning regimen (or in alternative FEAM regimen with fotemustine to replace BCNU) and reinfusion of CD34+ cells of ≥ 2x106/Kg CD34+ day 0 (optimal dose to reinfuse 4x106/Kg CD34+). G-CSF 5 mcg/Kg from day 2 until ANC&gt;1500/mmc. Patients who failed mobilization will directly proceed to rituximab maintenance</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ZEVALIN</intervention_name>
    <description>Infusion of 90Y Ibritumomab Tiuxetan if the patient has less than 25% BM infiltration at the pre-consolidation restaging (0.4 mCi/kg if platelets ≥150,000/mmc, 0.3 mCi/kg if platelets are between 100.000 and 150,000/mmc).</description>
    <arm_group_label>Arm A RIT</arm_group_label>
    <other_name>RIT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BEAM</intervention_name>
    <description>BEAM REGIMEN day -6 Carmustine* 300 mg/ m2 i.v. in 250ml dextrose 5% solution
from day -5 to day -2 Cytarabine 200 mg/m2 i.v. every 12 hours in 250 ml dextrose 5% solution, 250 ml/hr Etoposide 100 mg/m2 i.v. every 12 hours in 250 ml dextrose 5% solution, 250 ml/hr day -1 Melphalan 140 mg/m2 i.v. in 100ml saline solution in 200 ml/hr
day 0
UReinfusion of autologous stem cells following this rules:
Patient collecting ≥6x106 CD34+ cells/kg use &gt;4x106 CD34+ cells/kg for ASCT and keep &gt;2x106 CD34+ cells/kg for back up;
Patient collecting 4-6x106 CD34+ cells/kg use &gt;2x106 CD34+ cells/kg for ASCT and keep &gt;2x106 CD34+ cells/kg for back up;
Patient collecting 2-4x106 CD34+ cells/kg use all CD34+ cells for ASCT and keep no back up.
day 2 Filgrastim or Lenograstim 5μg/Kg s.c. until ANC &gt; 1500/mmc</description>
    <arm_group_label>ARM B ASCT</arm_group_label>
    <other_name>ASCT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-65

          -  Histologically documented diagnosis of grade I-IIIa FL defined according to WHO
             guidelines 2008 (Re-biopsy required)

          -  Availability of BM and PB for Minimal Residual Disease (MRD) analysis (see Appendix I)

          -  Relapsed or refractory disease after ≤ two chemotherapy lines at least one containing
             Rituximab (Rituximab maintenance is UNOTU considered a therapeutic line)

          -  Clinical indication of treatment i.e. Stage II-IV who require therapy according to SIE
             and GELF criteria (see Appendix II)

          -  ECOG performance status 0-2 (unless disease-related) (see Appendix III)

          -  Availability of histological material for centralized revision

          -  Laboratory values:

               -  ANC ≥ 1500/mmc unless due to marrow involvement by lymphoma and/or platelets ≥
                  100000/mmc unless due to marrow involvement by lymphoma

               -  Serum creatinine ≤ 1.5 x ULN, unless it is disease related

               -  Bilirubin ≤ 1.5 x ULN (or ≤ 3.0 x ULN, if patient has Gilbert syndrome)

               -  AST/SGOT and/or ALT/SGPT ≤ 2.5 x ULN if not lymphoma related or ≤ 5.0 x ULN in
                  case of lymphoma liver involvement

          -  Adequate cardiac function: LVEF &gt; 50% by echocardiography or MUGA scan

          -  Not pregnant or breast-feeding

          -  Willingness to use effective contraception during the study and 3 months after the end
             of treatment

          -  No other prior malignancies except for adequately treated non-melanoma skin cancer,
             carcinoma in situ of the cervix, or other cancer from which the patient has been
             disease-free for ≥ 5 years (see Exclusion criteria 14)

          -  Signed informed written consent

        Exclusion Criteria:

          -  Grade IIIb FL, transformed FL or histologies different from FL

          -  Previous treatment with &gt; two lines of chemotherapy ± rituximab Maintenance is UNOTU
             considered a therapeutics line)

          -  Previous ASCT or RIT treatment

          -  CNS involvement by lymphoma

          -  HBV positivity with the exception of patients who are seropositive because of
             hepatitis B virus vaccination and patients HbcAb positive and HbsAg negative with
             undetectable serum HBV-DNA. Occult carriers: must receive treatment with Lamivudine
             100 mg for the duration of treatment program and at least 12 months after treatment
             cessation; HBV-DNA levels and HBsAg will be monitored every month

          -  HCV positivity with elevated transaminases or INR or APTT or active virus replication

          -  HIV positivity

          -  Any concurrent medical condition requiring long term use (&gt; one month) of systemic
             corticosteroids

          -  Active bacterial, viral, or fungal infection requiring systemic therapy

          -  Any concurrent medical or psychiatric condition which might impair administration of
             therapy or preclude the ability to give informed consent

          -  Treatment with an experimental agent within 30 days prior to study entry

          -  Myelosuppressive chemo or biological therapy within three weeks before study entry
             (use rituximab course delivered as maintenance is not an exclusion therapy)

          -  Major surgery other than diagnosis within 4 weeks prior to study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Umberto Vitolo</last_name>
    <role>Principal Investigator</role>
    <affiliation>AO Città della salute e della Scienza di Torino - Ospedale S. Giovanni Battista - TORINO</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marco Ladetto</last_name>
    <role>Principal Investigator</role>
    <affiliation>AO SS. Antonio e Biagio e Cesare Arrigo Alessandria</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sonia Perticone</last_name>
    <phone>00390131206071</phone>
    <email>sperticone@filinf.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Francesca Massobrio</last_name>
    <phone>00390131206288</phone>
    <email>fmassobrio@filinf.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>U.O. Oncologia Presidio Ospedaliero N. Giannettasio</name>
      <address>
        <city>Rossano</city>
        <state>Cosenza</state>
        <zip>87067</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>A.O.U. San Martino</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandro Teresio Nati, MD</last_name>
      <phone>+39 010-5554316</phone>
      <email>sandro.nati@hsanmartino.it</email>
    </contact>
    <investigator>
      <last_name>Sandro Teresio Nati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ematologia, A.O. San Gerardo</name>
      <address>
        <city>Monza</city>
        <state>Milano</state>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Silvia Bolis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Niguarda</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chiara Rusconi, MD</last_name>
      <phone>+39 02 - 64442668</phone>
      <email>chiara.rusconi@ospedaleniguarda.it</email>
    </contact>
    <investigator>
      <last_name>Chiara Rusconi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS‐Centro di riferimento oncologico UO di ematologia e Trapianto Cellule Staminali</name>
      <address>
        <city>Rionero in Vulture</city>
        <state>Potenza</state>
        <zip>85028</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pellegrino Musto, M.D.</last_name>
      <phone>00390972726729</phone>
      <email>p.musto@crob.it</email>
    </contact>
    <investigator>
      <last_name>Pellegrino Musto, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera &quot;Bianchi Melacrino Morelli&quot;</name>
      <address>
        <city>Reggio Calabria</city>
        <state>RC</state>
        <zip>89125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caterina Stelitano, MD</last_name>
      <phone>+39 0522-296618</phone>
      <email>caterinastelitano27@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Caterina Stelitano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero &quot;A. Tortora&quot;</name>
      <address>
        <city>Pagani</city>
        <state>SA</state>
        <zip>84014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>, MD</last_name>
      <email>medint.nocera@libero.it</email>
    </contact>
    <investigator>
      <last_name>Catello Califano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emat Univ - Città della salute e della scienza di Torino</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federica Cavallo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Federica Cavallo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. S. Maria di Terni</name>
      <address>
        <city>Terni</city>
        <state>TR</state>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Marina Liberati, MD</last_name>
      <phone>+39 0744-205971</phone>
      <email>marinal@unipg.it;appolloniviviana@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Anna Marina Liberati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Bortolo</name>
      <address>
        <city>Vicenza</city>
        <state>VI</state>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Fabrizio Pomponi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Policlinico G.B. Rossi (Borgo Roma) Di Verona</name>
      <address>
        <city>Verona</city>
        <state>VR</state>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Fabio Benedetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. SS. Antonio e Biagio e C. Arrigo</name>
      <address>
        <city>Alessandria</city>
        <zip>15121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuela Zanni, MD</last_name>
      <email>manuela.zanni@ospedale.al.it</email>
    </contact>
    <investigator>
      <last_name>Manuela Zanni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica di ematologia AOU Umberto I Ospedali Riuniti</name>
      <address>
        <city>Ancona</city>
        <zip>60100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guido Gini, M.D</last_name>
      <phone>00390713580384</phone>
      <email>g.gini@ospedaliriuniti.marche.it</email>
    </contact>
    <investigator>
      <last_name>Guido Gini, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ematologia con Trapianto Policlinico Universitario Consorziale</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giorgina Specchia, Prof.ssa</last_name>
      <phone>00390805593471</phone>
      <email>g.specchia@ematba.uniba.it</email>
    </contact>
    <investigator>
      <last_name>Giorgina Specchia, Prof.ssa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia ed Oncologia Medica A. Seragnoli Policlinico S. Orsola</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Ospedale di Bolzano Divisione di Ematologia e Centro Trapianti di Midollo Osseo</name>
      <address>
        <city>Bolzano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Atto Billio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Tucci, MD</last_name>
      <phone>+39 030/3996269</phone>
    </contact>
    <investigator>
      <last_name>Alessandra Tucci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero A.Perrino - Divisione di Ematologia</name>
      <address>
        <city>Brindisi</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Angela Maria Melpignano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia Osp. Businco</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Giuseppina Cabras</last_name>
    </contact>
    <contact_backup>
      <email>cabras.giuseppina@tiscali.it</email>
    </contact_backup>
    <investigator>
      <last_name>Giuseppina Cabras, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCC Onco-Ematologia</name>
      <address>
        <city>Candiolo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Massimo Aglietta, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Garibaldi-Nesima</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Giuseppe Milone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Pugliese-Ciacci</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Ematologia ‐ Ospedale dell'Annunziata</name>
      <address>
        <city>Cosenza</city>
        <zip>87100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Policlinico Careggi Clinica Ematologica</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Luigi Rigacci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bosi Alberto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Ospedali Riuniti di Foggia</name>
      <address>
        <city>Foggia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Azienda Universitaria San Martino</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marco Gobbi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UO Ematologia con trapianto Ospedale Santa Maria Goretti</name>
      <address>
        <city>Latina</city>
        <zip>04100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>A O Papardo</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Donato Mannina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOC Ematologia Policlinico Universitario AOU G. Martino</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caterina Musolino, Prof.ssa</last_name>
      <phone>0039090344305</phone>
      <email>cmusolino@unime.it</email>
    </contact>
    <investigator>
      <last_name>Caterina Musolino, Prof.ssa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ematologia e Trapianto IRCCS, Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paolo Corradini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS San Raffaele Unità di Chamioterapia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrés J.M.Ferreris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico di Modena - Università degli studi</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stefano Sacchi, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Pascale Oncoematologia</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Antonello Pinto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SCDU Ematologia ‐ Università del Piemonte Orientale</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianluca Gaidano, Prof.</last_name>
      <phone>00390321660663</phone>
    </contact>
    <investigator>
      <last_name>Gianluca Gaidano, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Francesco</name>
      <address>
        <city>Nuoro</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Giancarlo Latte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Luigi Gonzaga Divisione di Ematologia</name>
      <address>
        <city>Orbassano (TO)</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera V. Cervello</name>
      <address>
        <city>Palermo</city>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Katia Patti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Complessa di Ematologia Ospedale di Parma</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Francesca Re</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ematologia Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luca Arcaini, M.D.</last_name>
      <phone>00390382503595</phone>
      <email>luca.arcaini@unipv.it</email>
    </contact>
    <investigator>
      <last_name>Luca Arcaini, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Maria della Misericordia</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Brunangelo Falini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Santo Spirito Dipartimento di Ematologia</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Francesco Angrilli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unità Ematologia Ospedale Civile di Piacenza</name>
      <address>
        <city>Piacenza</city>
        <zip>29100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annalisa Arcari, M.D.</last_name>
      <phone>00390523303737</phone>
      <email>a.arcari@ausl.pc.it</email>
    </contact>
    <investigator>
      <last_name>Annalisa Arcari, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOC Ematologia con TMO Ospedale San Carlo</name>
      <address>
        <city>Potenza</city>
        <zip>85100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Ausl Ravenna</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Monica Tani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SC Ematologia AO Santa Maria Nuova IRCCS</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Merli, M.D.</last_name>
      <phone>00390522296618</phone>
      <email>merli.francesco@asmn.re.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Merli, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.S.Andrea Reparto di Ematologia e Immunoematologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Maria Christina Cox, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univeristà La Sapienza</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alessandro Pulsoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Casa Sollievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Nicola Cascavilla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SC Ematologia Città della salute e della scienza di Torino</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Umberto Vitolo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASL BAT 1 Divsione di Ematologia</name>
      <address>
        <city>Trani</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Chiara</name>
      <address>
        <city>Trento</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Chandrakala Toldo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Filippo Gherlizoni</name>
      <address>
        <city>Treviso</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filippo Gherlinzoni</last_name>
      <email>filippo.gherlinzoni@aulss2.veneto.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UO Ematologia Osp. Cardinale Panico</name>
      <address>
        <city>Tricase</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vincenzo Pavone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica di Ematologia - A.O.U. S. Maria di Udine</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Francesco Zaja, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2013</study_first_submitted>
  <study_first_submitted_qc>April 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2013</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed follicular Lymphoma</keyword>
  <keyword>RIT</keyword>
  <keyword>Zevalin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

